Takeda Pharmaceutical Co Ltd (TKPHF) Change in Accured Expenses (2021 - 2026)

Takeda Pharmaceutical's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$219.0 million for Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 80.75% year-over-year to -$219.0 million; the TTM figure through Jun 2026 stood at -$217.2 million (down 149.2% YoY), while the FY2026 annual figure was -$542.1 million, down 2267.54% from the prior year.
• Change in Accured Expenses for Q2 2026 stood at -$219.0 million, down from $82.9 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $82.9 million in Q3 2025, with the low at -$341.4 million in Q2 2022.
• The 4-year median for Change in Accured Expenses is -$57.7 million (2024), against an average of -$80.7 million.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses tumbled 368.04% in 2022, then surged 169.36% in 2025.
• Takeda Pharmaceutical's Change in Accured Expenses stood at -$341.4 million in 2022, then surged by 115.14% to $51.7 million in 2024, then surged by 60.46% to $82.9 million in 2025, then tumbled by 364.02% to -$219.0 million in 2026.
• Business Quant data shows TKPHF's Change in Accured Expenses at -$219.0 million in Q2 2026, $82.9 million in Q3 2025, and -$121.2 million in Q2 2025.